Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | GVP, Chief Accounting Officer | May 19, 2025 | May 20, 2025 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | SVP, Controllership | September 22, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 19, 2025 · Filed May 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,173 |
Ending reported balance
After 2025-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-19 · Tax withholding · Disposed 996 · Balance 15,959 Row 2 · 2025-05-20 · Sale · Disposed 1,786 · Balance 14,173 F1: Trade made pursuant to a 10b5-1 plan executed on November 26, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Trade made pursuant to a 10b5-1 plan executed on November 26, 2024.
GILEAD SCIENCES, INC.
Report date September 22, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,455 |
Ending reported balance
After 2026-09-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-22 · Exercise / conversion · Acquired 2,223 · Balance 2,223 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2026-09-22 · Tax withholding · Disposed 768 · Balance 1,455 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 9,022 |
Reported balance
After 2026-09-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-22 · Exercise / conversion · Disposed 2,223 · Balance 9,022 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 23, 2026 20:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001927648-26-000005 · wk-form4_1790194631.xml · derivative · entry 3 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,022 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 22, 2026 Filed Sep 23, 2026 20:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 768 | $152.67 | $117,250.56 |
DisclosureSEC source: 0001927648-26-000005 · wk-form4_1790194631.xml · nonDerivative · entry 2 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,455 Read SEC document |
| September 22, 2026 Filed Sep 23, 2026 20:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001927648-26-000005 · wk-form4_1790194631.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,455 | $0.00 Strike: $148.56 | $0.00 |
DisclosureSEC source: 0001927648-26-000002 · wk-form4_1773347863.xml · derivative · entry 2 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,455 Underlying: Common Stock · 5,455 shares Expires 2036-03-10 F3 · derivative.exercise_date: The stock options have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001927648-26-000002 · wk-form4_1773347863.xml · derivative · entry 1 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,245 Underlying: Common Stock · 2,355 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 22, 2025 Filed Sep 23, 2025 23:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 8,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001927648-25-000009 · wk-form4_1758671755.xml · derivative · entry 1 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,890 Underlying: Common Stock · 8,890 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 20, 2025 Filed May 20, 2025 21:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,786 | $59.31 | $105,927.66 |
DisclosureSEC source: 0001048477-25-000060 · wk-form4_1747778300.xml · nonDerivative · entry 2 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,173 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 26, 2024. Read SEC document |
| May 19, 2025 Filed May 20, 2025 21:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 996 | $59.27 | $59,032.92 |
DisclosureSEC source: 0001048477-25-000060 · wk-form4_1747778300.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,959 Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 23:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,295 | $71.52 | $92,618.40 |
DisclosureSEC source: 0001048477-25-000041 · wk-form4_1742513921.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,955 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 26, 2024. F2 · balance_after: The Reporting Person's direct holdings have been adjusted by two shares to correct a previous clerical error. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 23:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 9,230 | $0.00 Strike: $71.55 | $0.00 |
DisclosureSEC source: 0001048477-25-000039 · wk-form4_1742341974.xml · derivative · entry 3 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,230 Underlying: Common Stock · 9,230 shares Expires 2035-03-16 F2 · derivative.exercise_date: Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 23:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000039 · wk-form4_1742341974.xml · nonDerivative · entry 2 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,252 F1 · price: Restricted stock units granted March 17, 2025. Price not applicable. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 23:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 823 | $69.44 | $57,149.12 |
DisclosureSEC source: 0001048477-25-000039 · wk-form4_1742341974.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,282 Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 01:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,344 | $68.38 | $91,902.72 |
DisclosureSEC source: 0001048477-25-000009 · wk-form4_1740532872.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,105 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 26, 2024. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 19:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 714 | $90.00 | $64,260.00 |
DisclosureSEC source: 0001048477-24-000128 · wk-form4_1723751821.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,449 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 29, 2023. Read SEC document |
| May 17, 2024 Filed May 20, 2024 21:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 993 | $76.97 | $76,431.21 |
DisclosureSEC source: 0001048477-24-000084 · wk-form4_1716240012.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,163 Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 19:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,286 | $90.00 | $205,740.00 |
DisclosureSEC source: 0001048477-24-000061 · wk-form4_1712948853.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,156 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 29, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 00:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 372 | $83.87 | $31,199.64 |
DisclosureSEC source: 0001048477-24-000050 · wk-form4_1710896100.xml · nonDerivative · entry 2 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,442 Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 7,050 | $0.00 Strike: $83.87 | $0.00 |
DisclosureSEC source: 0001048477-24-000050 · wk-form4_1710896100.xml · derivative · entry 3 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,050 Underlying: Common Stock · 7,050 shares Expires 2034-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000050 · wk-form4_1710896100.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,814 F1 · price: Restricted stock units granted March 15, 2024. Price not applicable. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 796 | $92.02 | $73,247.92 |
DisclosureSEC source: 0001209191-23-030736 · doc4.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,094 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 5,720 | $0.00 Strike: $87.74 | $0.00 |
DisclosureSEC source: 0001567619-23-005287 · doc1.xml · derivative · entry 2 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,720 Underlying: Common Stock · 5,720 shares Expires 2033-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 3,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-005287 · doc1.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,890 F1 · price: Restricted stock units granted on March 15, 2023. Price not applicable. Read SEC document |
| May 16, 2022 Filed May 19, 2022 00:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 17,490 | $0.00 Strike: $77.32 | $0.00 |
DisclosureSEC source: 0001567619-22-011218 · doc1.xml · derivative · entry 2 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,490 Underlying: Common Stock · 17,490 shares Expires 2032-05-15 F2 · derivative.exercise_date: Option grant vests 12/48th on May 16, 2023 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| May 16, 2022 Filed May 19, 2022 00:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011218 · doc1.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · GVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,130 F1 · price: Restricted stock units granted on May 16, 2022. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.